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Abstract: Wildlife has often presented and suggested the effects of endocrine disrupting chemicals
(EDCs). Animal studies have given us an important opportunity to understand the mechanisms
of action of many chemicals on the endocrine system and on neurodevelopment and behaviour,
and to evaluate the effects of doses, time and duration of exposure. Although results are sometimes
conflicting because of confounding factors, epidemiological studies in humans suggest effects of
EDCs on prenatal growth, thyroid function, glucose metabolism and obesity, puberty, fertility, and on
carcinogenesis mainly through epigenetic mechanisms. This manuscript reviews the reports of a
multidisciplinary national meeting on this topic.
Keywords: Endocrine Disrupting Chemicals (EDCs); neurodevelopment; autism; obesity; puberty;
fertility; thyroid function; epigenetics; carcinogenesis; growth
1. Man-Made Environmental Endocrine Disrupting Contaminants: Impact on Wildlife and
Human Health
Numerous xenobiotic chemicals used in everyday life and released into the environment by
human activity, have the potential to disrupt the endocrine system of wildlife and humans at
ecologically relevant concentrations. Of approximately 85,000 known chemical products, approximately
1000 are recognised as potential endocrine disruptors. These include plasticisers as phthalates and
bisphenol A, flame retardants, industrial chemicals including alkylphenols, metals and dioxins,
air pollutants such as polycyclic aromatic hydrocarbons, and pesticides.
The endocrine system plays a central role in all vertebrates and regulates important biological
functions as metabolism, development, reproduction, and behaviour. Since the presentation of the
endocrine-disrupting contaminants hypothesis [1] a new emerging science has arisen with concerns
relative to the effects of endocrine disrupting contaminants on health and environment [2]. This hybrid
multidisciplinary science incorporates findings and methodologies from different disciplines including
toxicology, endocrinology, developmental biology, molecular biology, ecology, behavioural biology
and epidemiology [2]. An endocrine disruptor is defined as “an exogenous chemical, or mixture of
chemicals, that can interfere with any aspect of hormone action” [3]. These chemicals can bind to the
body’s endocrine receptors to activate, block, or alter natural hormone synthesis and degradation
which occur through a plethora of mechanisms resulting in “false” lack or abnormal hormonal signals
that can increase or inhibit normal endocrine function [3]. Data from ecological studies, animal models,
clinical observations in humans, and epidemiological studies agree to consider endocrine disrupting
chemicals (EDCs) as a significant for wildlife and human health [2,4].
1.1. Lesson from Wildlife
Early experimental work was driven by ecological studies that pointed out an association between
a complex mixture of xenobiotic pollutants and endocrine disruption of reproduction and development
in fish, reptiles (e.g., alligators, turtles), birds, and mammals living in the Laurentian Great Lakes
of North America [5,6]. The observed effects suggested estrogenic, androgenic, anti-androgenic,
and antithyroid actions. Abnormalities in organs, physiology and behaviour vary from subtle changes
to permanent alterations, including disturbed sex differentiation with feminized or masculinized sex
organs, changed sexual behaviour, altered immune function, and egg-shell thinning in birds with
severe population declines in a number of raptor species in Europe and North America [5,7,8]. Another
example are male alligators exposed in ovo (as embryos) to various pesticides which subsequently
exhibited significantly reduced plasma testosterone concentrations, aberrant testicular morphology,
and small penis size while females exhibited ovarian abnormalities associated with reduced fertility
and high embryonic mortality [5,8].
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From an evolutionary perspective, the vertebrate-type sex steroid hormones used as regulator
of reproduction and development appeared in invertebrate during the evolution of Deuterostomes
(Echinoderms and Chordates). Among Protostomes (i.e., Arthropods: insects and crustaceans) steroid
molting hormones such as ecdysone have become important regulators of growth, development
and reproduction [9]. Several studies have reported reproductive and developmental adverse effects
after chronic exposure to EDCs acting as receptor agonist/antagonists of ecdysone and of juvenile
hormones [10,11]. Data accumulated over the past two decades reveal substantial global contamination
of EDCs by intentional or accidental release into the environment and incorporation into consumer
products. An important issue is whether the abnormalities reported in wildlife provide a warning
to human health. In this context it should be noted that the vertebrate neuroendocrine system is
a clear example of the evolutionary homology principle, as that its development and organization
is substantially conserved and similar across the various classes. Indeed, it is not surprising that
for centuries wildlife has acted as a sentinel for human health [2,12]. Currently, there are nearly
1000 chemicals reported to have endocrine effects; in addition, new chemicals enter the marketplace
each year and the vast majority of them are developed with poor or inappropriate toxicological testing
for the detection of potential endocrine disruption [13].
1.2. Animal Models: Evidence, Clinical and Epidemiological Studies
There is strong evidence gained from laboratory studies showing the potential of several
environmental chemicals to cause endocrine disruption at environmentally relevant exposure levels.
Indeed, it is important to underline that similarly to the natural hormones, EDCs can produce profound
effects on development at very low dose levels of exposure being pre and early postnatal exposure the
most vulnerable periods of life.
Traditional toxicology used doses considered to date as elevated, within the range of parts per
million, and evaluated gene mutations, weight loss and death. Current data have evidenced that even
very low doses of EDCs (parts per billion and parts per trillion) can cause effects in animals, and several
studies have shown in this respect both gene suppression and gene activation [13–15]. Given the
identification of low-dose effects, which differ from those observed at high doses, the importance
of the timing of exposure and the recognition of unique effects during development make previous
assumption “the high dose makes the poison” used in risk assessment, simplistic and invalid for many
environmental chemicals [2,13,14]. Studies on intrauterine positioning of foetuses in rodents and other
animals have proved clearly how low doses of hormones can affect many phenotypes.
In particular, the rodent uterus is an excellent model to study how very low doses of
hormones released from neighbouring fetuses can influence the development of endocrine-sensitive
morphological and behavioural endpoints in male and female mice [14,16].
Testosterone production in male mice begins around the 12th day of gestation and transfers
passively to neighbouring foetuses, so that if a foetus is positioned between two male neighbours
it receives higher concentrations of this hormone than a foetus positioned between one male and
one female or between two females. Very small differences in testosterone exposure influence then
a variety of endpoints including male and female behavioural phenotypes, many of which become
apparent only during or after puberty [14,16]. An important issue related to toxicological studies on
neurobehavioural effects caused by low dose exposure to EDCs in utero and early development is the
lack of evolutionary perspective (i.e., adaptive function). Most of the neurobehavioural endpoints used
to study EDC exposure, evolved through Darwinian socio-sexual selection and are sexually-dimorphic
therefore, an ethological approach (referred to as ethotoxicological approach) becomes of upmost
importance: animals must be tested at different stages of their development, in the appropriate context
allowing the functional expression of sex related behaviour/s [17]. For example, bisphenol A (BPA)
causes harm in animals at levels to which humans are exposed on average. BPA has the ability to
bind to estrogen receptors and initiate cellular responses similar to those caused by estradiol. Recent
experiments have shown that at “low doses”, previously predicted to be safe, BPA causes dramatic
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adverse effects that include chromosomal damage in developing mouse oocytes, and abnormalities
in the entire reproductive system in male mice, including a decrease in testicular sperm production
and decreased fertility. In this context, EDCs such as phthalates and BPA might be involved in
increased hypospadias, male infertility (reduction in sperm counting in the semen), and neurocognitive
development [14,18,19]. Epidemiological studies linked EDCs, including dioxins, phthalates, and BPA
with reproductive effects, neurobehavioural and metabolic syndrome, bone disorders, immune
disorders, and cancers in humans. Animal studies show associations with many additional health
effects, including asthma, learning and behavioural problems, early puberty, Parkinson’s disease,
breast and prostate cancer, obesity, and other diseases. Indeed, recent epidemiological studies have
found significant associations between gestational levels of both BPA and phthalates and cognitive
impairment and aggressive behaviours, in animal models [19–21] and attention deficit hyperactivity
disorder (ADHD) in children [22,23]. The common thread is that exposure to low doses of BPA in
utero and during early postnatal life disrupts the development of normal dimorphic behaviours,
thus affecting males and females differently [3,15,19–21]. Therefore, the most consistent and robust
finding across the recent literature on different mammalian species, including humans, is that
whenever both sexes have been examined, sex is a fundamental variable in defining BPA effects
on behaviour [20,21]. At present, the increase in non-communicable diseases has been related to
the exposure to EDCs; these diseases include cancers, endometriosis, infertility, obesity, diabetes,
early puberty, susceptibility to infections, autoimmune diseases, ADHD/learning disabilities,
neurodegenerative diseases, asthma, and heart disease [4].
1.3. Transgenerational Effects, Epigenetics and Sustainability
Recent evidence indicates that exposure to EDCs during development not only can directly
harm the exposed individual, but also the individual’s offspring and future generations, a process
that is referred to as transgenerational inheritance [24,25]. The data showing these effects led to
a new paradigm for non-communicable disease: the developmental origins of health and disease
(DOHaD) [4]. The worldwide increase in neurodevelopmental disabilities, including autism, ADHD,
infant/childhood depression, social disorders and dyslexia, have been related to industrial chemicals
acting as neurotoxicants in the developing brain [26]. Thousands of animal studies show direct causal
relationships between a chemical exposure in utero and disease outcomes and in some instances,
the adverse effects can be transmitted to subsequent generations through transgenerational epigenetic
inheritance (e.g., [24,25,27]). The emerging body of research suggests that exposure to EDCs could
have consequences not only for our own health and for that of our children, but also for the health of
the generations to come. Indeed, several chemicals, including some EDCs, have the potential to cause
health effects in the offspring of exposed individuals through environmentally induced epigenetic
modifications. Thus, if we continue to allow human exposure to chemicals with endocrine activity this
could affect the sustainability of the wildlife and of the human population. Considered their “stealth”
nature, we are currently unprepared to detect the effects of EDCs. EDCs represent one the main factors
that can substantially contribute to compromise the sustainability of our environment [1,2]. Therefore,
precaution dictates that we cannot wait for “conclusive” evidence of harm to human populations to take
action. A more effective communication among scientists, business leaders, regulators, and politicians
is required to facilitate science-based decision making.
2. Current Knowledge on Exposure to EDCs and Neurobehavioural Development: Lessons
from Animals
The increased rates in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases,
have been linked to developmental exposure to environmental pollutants [28]. There is strong evidence
that one of the most prevalent EDCs, BPA, in addition to causing several adverse effects described
in other sections of this review, is a neuroendocrine disruptor at environmentally relevant (within
the levels of human exposure) “low” doses and can interfere with sexual differentiation processes in
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animal models [20,21]. Emerging research on maternal EDC exposure and child neurodevelopmental
outcomes have recently found significant associations between gestational levels of BPA or phthalates
with alterations of emotional behaviour, aggressive behaviour, cognitive impairment and ADHD in
children [20,22]. After more than two decades of experimental research, animal studies have shown
that maternal exposure to BPA during gestation and/or lactation induces long-term alterations in
offspring behaviour, including mainly three behavioural categories: (1) anxiety and exploration;
(2) learning and memory; and (3) socio-sexual behaviours across mammalian species. In addition,
treatment with EDCs can also affect mothers’ behaviour. In the following sections, the most relevant
findings on EDCs effects on neurobehavioural development in animal models and in epidemiological
studies are reported, focusing mainly on BPA, the most studied EDC in the last decade. BPA in the
brain has been shown to act primarily as a weak estrogen receptor agonist and as an antiandrogen,
and to cause epigenetic changes altering gene expression in different regions [27,29]. We discuss here
several studies reporting behavioural effects of prenatal (gestational) and/or postnatal (lactational)
exposure to BPA at environmentally relevant “low” doses (below the reference dose of 50 µg/kg
bw/day traditionally considered the tolerable daily intake or TDI) via maternal treatment.
2.1. Anxiety and Exploration
Despite differences in species, strain and methodology, there is a consistent set of data
demonstrating that perinatal exposure to low doses of BPA increased anxiety-like behaviours in
different rodent models and using different test paradigms. In particular, BPA exposure reduced
exploration and increased anxiety-related behaviours measured through the elevated plus maze test,
open-field and dark-light chamber tests in mice [30–38], rats [37,38] and other rodent species [39,40].
These BPA-induced effects on anxiety behaviours have been associated with altered mesolimbic
dopaminergic signalling, increased expression of glucorticoid receptors in the hippocampus, or with
reduction in estrogen-dependent gene expression in the amygdala [32,35,36]. The brain alterations
associated with BPA exposure and increased anxiety, are generally sex-dependent and/or alter
normal sex differences observed in the control population [20,21,36,37]. Although there are relatively
few studies in humans, findings from epidemiological studies are consistent with data in animal
models associating maternal BPA levels to internalizing behaviour in children, including anxiety and
depression [41–44].
2.2. Learning and Memory
Prenatal and early postnatal BPA exposure were associated with changes in cognitive responses,
socio-sexual interactions, play behaviour and parental care in rodents, non-human and human
primates [20]. More specifically, impairment in spatial learning and memory have been reported in male
deer mice [39], rats [45] and mice [46] perinatally exposed to BPA. In non-human primates, prenatal
exposure to low-dose BPA decreased synaptic spine density in the hippocampus and prefrontal cortex.
Although the experimental evidence is limited, these studies suggest that BPA may impair memory
formation by interfering with neural plasticity processes. Two epidemiological studies have come to
conflicting conclusions, one reporting significant maternal BPA-associated cognitive impairment in
children [47], the other with no significant correlation [48].
2.3. Socio-Sexual Behaviour
With regard to Socio-Sexual Behaviour, a few studies highlighted a reduction of social interactions
in BPA-exposed animals; BPA decreased play behaviours in male juvenile cynomolgus monkeys after
BPA exposure during gestation, [49] while in rats, reduced female social play [50] and male sexual
approach behaviours [51] were reported. A study in mice reported increased play behaviour and
social investigation in BPA-exposed juveniles; in addition, the observed effect was transgenerationally
transmitted up to the third generation, without further treatment, suggesting an epigenetic effect
of BPA exposure via the germ line [27]. During development, rats and mice exposed to prenatal
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BPA showed decreased oxytocin and vasopressin gene expression that may contribute to explain the
observed behavioural changes [27,37]. Thus, age at testing, developmental stage of exposure, sex and
other variables can influence BPA effects on social behaviours. With regard to human studies, some
evidences indicate sex-dependent associations between gestational BPA or phthalate exposure with
alterations in social and aggressive behaviours in children and adolescents [41,42,52,53].
2.4. Maternal Behaviour
Direct exposure to EDCs may affect maternal behaviour of treated females and alter the
delicate, reciprocal mother-pup relationships [54]. Maternal exposure during pregnancy to a low,
but environmentally relevant BPA dose, through a non-stressful administration procedure (i.e.,
allowing pregnant female mice to drink corn oil in which BPA was dissolved) produced subtle
alterations in maternal behaviour and in the behavioural development of their offspring [55].
Specifically, mice fed 10 µg/kg BPA during late pregnancy showed a reduction of subsequent
maternal nursing behaviour and an increase of time spent away from the nest over the first 2 weeks
post-partum. Further studies in rats [56,57], mice [31,58], voles [59] and California mice [60] confirmed
changes in maternal behaviour following exposure to BPA and other EDCs during gestation and
lactation. These findings suggested that pregnancy and lactation represented “vulnerable periods
of development” for the mother and that maternal brain, physiology and behaviour were highly
sensitive to endocrine disruption. Perinatal BPA exposure may also decrease the female offspring
engagement in maternal cares in mice and rats [55,56,58] indicating transgenerational impact of BPA
exposure on the neuroendocrine substrates modulating maternal behaviour. It is well recognised
that in rodents, variation in maternal care per se can affect the offspring growth rate and the
subsequent neuroendocrine and behavioural responses that was shown to be associated with epigenetic
exposure [54,61]. This implies that an analysis of maternal behaviour should be included, or at least
considered as a possible variable, when assessing the effects of chemicals administered via maternal
treatment [54].
2.5. EDCs Effects Are Sex-Specific
Previously reported studies proved that BPA at low, environmentally relevant doses can affect
behaviour in animal models and epidemiological evidence is also growing. Specific effects of BPA on
behaviour can vary because of differences in study design, animal models, behavioural endpoints, etc.
Recent evidence has repeatedly shown in several mammalians, including humans, that the effects of
BPA on behaviour differ in males and females.
Normal sex-differentiated behaviour, with differences observed in males and females are present
after exposure to BPA in utero and in early postnatal life [20,21,62]. The most consistent and robust
finding across the recent literature on several mammalian species, including humans, is that sex is
a fundamental variable in accounting for BPA effects on behaviour. Numerous studies have also
confirmed the ability of BPA and other EDCs to affect rodent developing brain in a sex specific way
even at very low doses by disrupting normal steroid programming of the brain through epigenetic
alterations that can lead to differential gene expression [63]. Unfortunately, it is not clear how
the various sex-specific behavioural differences found in rodent models will translate to humans.
However, sex specific effects of BPA exposure seem to be a feature also in human epidemiological
studies [20,64]. Prenatal BPA levels are positively associated with increased externalizing behaviours
in girls [44], increased internalizing behaviours, anxiety and aggression in boys [41,43]. Since many
neuropsychiatric disorders show a sex–specific incidence, it is important to unravel how hormones
and other factors shape neurobehavioural dimorphisms. An additional consideration is that whenever
considering any developmental factor, sexually dimorphic consequences that need to be accounted
for. In view of the fundamental and more consistent results linking BPA exposure to behavioural
effects by altering brain sexual differentiation, endocrine disruption studies must examine sexual
dimorphic behaviours.
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3. EDCs and Neurodevelopmental Diseases in Humans: Focus on Autism
Disability originating from neurodevelopmental disorders is extremely common affecting more
than 10% of children [65,66]. The most common neurodevelopmental disorders include learning
disabilities, sensory deficits, developmental delays, attention deficit and hyperactivity disorder and
autism, which is the most severe and costly [67] due to the associated permanent disabilities.
The causes of autism spectrum disorder (ASD) remain elusive despite a large amount of basic
and clinical research performed over the last ten years. There are consistent reasons to think that ASD
is already present at birth; several neurological changes have been reported to develop during fetal
life in response to various and heterogeneous factors. The role of genetic abnormalities in autism has
stimulated a huge amount of research, however, the final scenario does not satisfy the expectation.
Many twin and family studies point out the importance of inherited predisposition to the disorder
although epidemiologic research suggests the strong contribution of prenatal and early postnatal
environmental factors. Indeed, genetic factors alone account for approximately 20–30% of all cases,
whereas 70–80% are the result of complex interactions between environmental risk factors and inherited
or de novo genetic susceptibility [68]. Though the prevalence of autism is undoubtedly increasing over
time [65], it is not clear if this increase is due to diagnostic improvement or to a greater susceptibility of
the population to this disease. Recent studies point to an equal contribution of environmental factors,
particularly environmental toxicants, and genetic susceptibility [69]. Only few industrial chemicals
(e.g., lead (Pb), methylmercury, polychlorinated biphenyls (PCBs), arsenic (As), and toluene) are
recognized causes of neurodevelopmental disorders and subclinical brain dysfunction. The recent
discovery that heavy metals such as cadmium (Cd), As, mercury (Hg), nickel (Ni), and Pb may exhibit
endocrine-disrupting activity in animal models, probably by interfering with zinc-fingers of nuclear
estrogen receptors [70].
3.1. Hg
Hg represents the most studied compound in relation to the risk of autism. A recent review [71]
considered studies, published between 1999 and 2016, examining the potential relationship between
Hg and ASD, including studies on Hg levels in human tissue, biomarkers for Hg exposure,
and epidemiological studies. Referring to this comprehensive review, four studies reported that
some brain auto-antibodies correlated with Hg levels in children with ASD, finding that is biologically
plausible since previous studies reported that exposure to Hg, in particular to the Hg-based compound
Thimerosal, caused autoimmune dysfunction [72–75].
Several epidemiological studies were carried out to check if thimerosal in vaccines was a risk factor
for ASD, the majority confirming that thimerosal in vaccines was a risk factor for ASD, a minority found no
associations [71,76–79]. A number of studies examined susceptibility to Hg (or “pro-oxidant environmental
toxins”) in ASD. These studies used a variety of tissues, including brain tissue, lymphoblastoid cell
lines (LCLs), and blood samples [71,80–82]. A major focus was trans-methylation/trans-sulfuration
concentrations, which were consistently found to be abnormal in ASD [83,84]. It was concluded that
children with ASD had increased oxidative stress and reduced detoxification capacity due to limited thiol
availability and decreased glutathione (GSH) reserve capacity [71,85–87].
Furthermore, a few human tissue studies described in blood (whole blood and red blood cells)
and nails, higher Hg levels in those with the worse symptoms [88–90].
Increased urinary coproporhyrin (cP), pentacoproporphyrin (5cxP), and the presence of
precoprpophyrin (prcP), an atypical porphyrin, which is not found in the urine of unexposed controls,
proved Hg toxicity and Hg body burden. Finally, relationships between ASD severity and porphyrin
biomarkers of Hg exposure have been described [71,91,92].
The presence of Hg in air pollution has also been regarded as a risk factor for ASD [71,93,94].
In conclusion, the vast majority of these studies suggested Hg as an ASD risk factor, describing
both direct and indirect effects. The preponderance of the evidence indicates that Hg exposure is
causal and/or contributory to ASD.
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3.2. PCBs
PCBs have the strongest and longest-known associations with neurological disorders. In humans,
there is evidence for impaired neurodevelopment, lower intelligence level (IQ), and problems with
attention, memory, and fine motor skills such as writing. PCBs have been recognized as persistent
organic pollutants, and for this reason were banned in almost all countries many years ago. However,
due to their lipophilic nature, PCBs have bio-accumulated in the food chain, and currently PCBs
levels are still measurable in blood samples, including those from pregnant women, and breast milk
samples. In a recent population-based case-control study in southern California 11 PCB congeners
were measured in banked second trimester serum samples relative to ASD (N = 54), intellectual deficit
(ID) (N = 181), and general population (GP) controls (N = 418) [95]. ASD risk was elevated for a
number of PCB congeners, particularly for those showing a concentration within the highest quartile
(AOR = 1.79, 95% CI 1.10, 2.71). For all these compounds, the first evidence of a potential neurotoxicity
came from the detection of acute adverse effects on the adult nervous system, at high doses, followed
by case reports and epidemiological evidence on developmental toxicity at lower doses, to which
children were exposed. Exposure to these chemicals during early fetal development can cause brain
injury at doses much lower than those affecting adult brain functions.
3.3. Polycyclic Aromatic Hydrocarbons (PAHs)
Recently, a considerable amount of research has studied whether PAHs, the main air pollutants,
are harmful for the brain. Undoubtedly, the most important study on PAHs is the american study on
Childhood Autism Risks from Genetics and the Environment (CHARGE study). This study assessed
residential traffic exposure in a group of children with autism diagnosed between 24 and 60 months
of age (N = 304) and in normally developing matched controls (N = 259). Children allocated in the
highest quartile of exposure for the average concentrations of several pollutants, including nitrogen
oxides, PM10, PM2.5, and nitrogen dioxide (NO2), during the entire duration of pregnancy and the
first year of life had a higher risk of autism compared to those in the lowest quartile [96]. Additionally,
the distance from a freeway, a significant source of air pollution, was more likely to be smaller in cases
compare to controls (≤309 m) [97].
3.4. Polybrominated Diphenyl Ethers (PBDEs)
Since the 1970s to reduce the risk of combustion, synthetic flame retardants as PBDE have been
used extensively and have accumulated ubiquitously in the environment. PBDE has been detected
in human serum, placenta, adipose and liver tissue, cord serum and breastmilk besides in-house
dust, soil, sewage sludge and wildlife [98]. The impact of prenatal and postnatal PBDE exposures
on child behaviour has been investigated by a number of epidemiologic studies, recently reviewed,
reporting conflicting results [99]. Some of the studies showed a positive association between serum
and milk median levels of PBDEs and abnormalities in children behaviour, while others failed to
show any associations. Despite these conflicting results, it was concluded that prenatal and postnatal
PBDE exposure affected adversely externalizing behaviour (e.g., hyperactivity and conduct problems).
Therefore, additional studies are needed to determine whether PBDEs are associated with internalizing
problems, adaptive skills, and social behaviours/ASD in children.
3.5. Phthalates
Phthalates, ubiquitous contaminants, are used as plasticizers, solvents and additives in many
consumer products (i.e., vinyl flooring, wall coverings, food containers and cosmetics). In particular,
di-(2-ethylhexyl) phthalate (DEHP) represents one of the most commonly used plasticizers in
pharmaceutical and medical devices. A recent systematic review on the association between prenatal
and/or childhood exposure to phthalate and ASD highlighted the existence of a limited number of
studies on the topic, as only seven were considered of relevance [100]. Of these, two did not measure
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phthalate exposure, therefore did not yield quantitative results, whereas the remaining five studies
measured phthalate exposure in biological samples. Two were cohort studies, one reporting a positive
association and one with unclear results; three were case-control studies, two reported a significant
correlation between exposure to phthalate and ASD, while the third bared negative results though it
showed a compromised phthalate metabolite glucuronidation pathway, as a possible mechanism for ASD.
3.6. BPA
BPA is another ubiquitous xenobiotic agent suspected to cause adverse effects on human health.
This common plasticizer is used in the manufacturing of polycarbonate plastics and polyvinyl chloride
(PVC), as an antioxidant in some plasticizers, and in epoxy resins used to coat the inside of many
food and beverage cans. Only one study has specifically addressed the possible association between
BPA and autism [101]. In this study, urine specimens were collected from 46 children with ASD and
52 controls. Total BPA concentration, determined by mass spectrometry, was 3 times greater in the
ASD group compared with controls suggesting an association between BPA and ASD.
3.7. Pesticides
Pesticides are neurotoxic, and associations with ASD symptoms, organochlorine (OC),
organophosphate (OP), and pyrethroid pesticide exposure during pregnancy have been reported.
The most important study in this context is the CHARGE study [102]. The aim of this study was to
investigate if residential proximity to agricultural pesticides during pregnancy was associated with
ASD or developmental delay (DD).
The California Pesticide Use Report (1997–2008), linked commercial pesticide application
data to the addresses of 970 participants during pregnancy and aggregated pounds of active
ingredient applied for OP, OC, pyrethroids, and carbamates with 1.25-km, 1.5-km, and 1.75-km
buffer distances from the homes. The study concluded that the risk of ASD increased by 60% in
those exposed to organophosphates during gestation and that the risk was greater if this occurred
during the third-trimester (OR = 2.0; 95% CI: 1.1, 3.6) or the exposure was to chlorpyrifos during the
second-trimester (OR = 3.3; 95% CI: 1.5, 7.4).
Children of mothers living just before conception or during the third trimester near areas where
pyrethroid insecticide was used, presented a greater risk of both ASD and DD (ORs ranging from 1.7
to 2.3). The risk for DD was increased in particular in those living close to zone where carbamate was
used, but no specific vulnerable period was identified. These evidences strengthen the evidence linking
neurodevelopmental disorders with gestational pesticide exposure, particularly to organophosphates,
and provide novel results relative to associations between ASD and DD and exposure to pyrethroids
and carbamates.
4. EDCs and Metabolism
In the last decade emerging evidence has indicated a role for EDCs in the etiology of obesity [103].
In May 2014 a workshop held in Parma produced The Parma Consensus Statement proposing the
Metabolism Disruptor Chemicals (MDCs) hypothesis, which postulates that many endocrine disruptors
have the ability to promote obesity, diabetes, fatty liver and/or alterations in lipid and glucose
metabolism in humans and animals [4]. Overall, these metabolic alterations may play an important
role in the global epidemics of obesity, type 2 diabetes (T2D) and Metabolic Syndrome (MetS). It is
important to point out that food intake and exercise play an essential role in controlling body weight,
but many EDCs can act as MDCs and alter the set-point for gaining weight. Experimental data have
shown that EDCs exposure during development can act at different levels on multiple tissues and
pathways to increase food intake and metabolism, leading to weight gain by altering the set-point of
sensitivity to develop obesity and associated metabolic disorders [4,26]. Indeed, BPA, for example,
not only can cause weight gain but also lead to glucose intolerance, T2D and fatty liver in mice [104].
The same has been noticed for some phthalates and tributyltin [26]. By definition EDCs interfere with
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hormonal actions and sex hormones influence body adiposity and show changes in the metabolic
syndrome [105]. Sex specific effects are expected for many EDCs [4], and in fact sex biased effects
of developmental exposure to BPA or other EDCs on body weight and metabolic functions have
been reported depending upon type and dose of the tested chemical, the timing of exposure and the
metabolic challenge [26].
5. MDCs and Neuroendocrine Circuits Controlling Food Intake and Energy Metabolism
MDCs are compounds characterized by several peripheral targets (e.g., fat tissue, liver, pancreas,
skeletal muscle, intestine), that may also act at the level of hypothalamic neuroendocrine circuits [26].
The hypothalamus (with some structures in the brainstem, as the nucleus of the solitary tract), plays
an important role in energy balance regulation and food intake, with two distinct populations of
neurons located in the arcuate nucleus (ARC), exerting opposite effects on food intake and energy
metabolism [106,107]. One group of neurons expresses the orexigenic neuropeptides Y (NPY) and
Agouti Related (AgRP), and receptors for peripheral hormones signalling the energy status of the body
(insulin, leptin and ghrelin). An increase in NPY/AgRP release results in increased food intake and
decreased energy expenditure. Other ARC neurons produce the neuropeptide melanocyte-stimulating
hormone (MSH), which derives from pro-opio-melanocortin (POMC), and the neuropeptide Cocaine-
and amphetamine-regulated transcript (CART), both involved in peripheral energy status signalling.
In particular, the release of MSH/CART decreases food intake and increases energy expenditure.
Peripheral signals (hormones like insulin, leptin and ghrelin, in addition to sensory nerve fibres)
carry information concerning energy stores, food processing, and gastrointestinal activity. The current
hypothesis is that as fat tissue increases, both insulin and leptin levels increase along with MSH
expression, while NPY synthesis and release are inhibited, resulting in a decrease in food intake.
On the contrary, when NPY synthesis and release are increased and MSH is decreased, there is an
increase in food intake. Dysfunction of the NPY system has been implicated in obesity and T2D
in humans [108]. Both the neuronal systems located in the ARC nucleus send their fibres to the
hypothalamic nuclei, are important for metabolic control, the most important being represented by one
the paraventricular nucleus (PVN). The two most important hypophysiotrophic systems regulating
body metabolism are located in the PVN: the Corticotropin releasing hormone (CRH) neurons,
controlling the hypothalamus-hypophysis-adrenal axis (HPA) [109] and the Thyrotropin-releasing
hormone (TRH) neurons, controlling the hypothalamus–hypophysis–thyroid axis (HPT) [110]. The MSH
system, is sexually dimorphic with females having increased responsiveness to leptin and decreased
responsiveness to insulin in comparison to males [111]. The NPY/AgRP circuit is also sexually
dimorphic. In particular, NPY immunoreactivity is sexually dimorphic in the ARC, the dorsomedial
hypothalamus, and the PVN [112] and the Neuropeptide Y receptor Y1 (NPY-Y1) expression is higher
in females compared to males [113]. Both peripheral (e.g., estrogens) and central hormones cooperate
in the control of these two main circuits, resulting in the balance between anabolism and catabolism,
and the stimulation or the repression of food intake [114]. All the components of these systems
(neuropeptides, receptors, signalling molecules) may be targets of the MDCs action, however, only
a few studies have investigated alterations of neural circuits/cells in relation to feeding behaviour
and energy balance output [26,115]. Among the most studied MDCs are BPA and Tributyltin (TBT).
The exposure to low doses of BPA in mice during the prenatal period alters food intake during puberty
and in adulthood, as well as leptin and insulin levels, which in turn regulate the NPY system [104].
In addition, prenatal treatment with BPA has a sexually differentiated organizational effect on the
MSH and NPY systems [116]. Interestingly, these differences are evident only if adults are exposed to
a high-fat diet. Under these conditions, male mice showed reduced MSH fibre innervation of the PVN
and increased NPY/AgRP mRNA in the ARC, while females showed reduced POMC mRNA in the
ARC, reaching a level similar to that observed in males, suggesting a masculinizing effect of BPA.
With regard to TBT, it is one of the organotin compounds well known for its obesogenic effects,
mediated by the Peroxisome Proliferator Activated Receptor Gamma (PPARγ) receptors on the fat
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tissue [117]. Different studies on mice showed that prenatal exposure to TBT induces hypothyroidism
in the progeny; in pregnant females a dose-dependent increase in Triiodothyronine(T3)-independent
TRH transcription levels was observed [118,119]. Another study showed that acute exposure to TBT
resulted in an activation of neurons in a crucial region for the regulation of food intake, the ARC,
thus suggesting a direct action of this compound on the nervous system [120]. Chronic exposure to
TBT induced, in adult male mice only, profound alterations of the leptin-NPY-NPY-Y1 system [89],
and of the POMC system [121]. Moreover, in adult rats, exposure to TBT induced a sexually expression
of mRNA for NPY and POMC [122]. An additional study in rats demonstrated that TBT induces a
functional dissociation between CRH, Adrenocorticotropic hormone (ACTH) and corticosterone, and
an increase in the expression of nitric oxide synthase in the hypothalamus [123]. The specific action of
TBT on the NPY and MSH systems is probably linked to the expression of PPARγ receptors in both
neuronal types [124]. In conclusion, despite the limited number of studies on the effects of MDCs in
the regulation of food intake and metabolism, the neuroendocrine circuits implicated in their control
are important endpoints for the obesogenic action of these compounds, probably mediated by the
interaction with PPARγ receptors.
6. Effects of EDCs on Glucose Metabolism and Obesity
Obesity, Insulin Resistance (IR) and T2D are related metabolic disorders with a prevalence that
has dramatically increased worldwide and at any age over the last decades. The etiology of these
conditions is multi-factorial, with lifestyle and genetic background playing a dominant role. However,
in recent years, experimental and epidemiological data from the literature suggest an important
contribution of EDCs in the onset of obesity and on glucose metabolism impairment as in part detailed
in the previous paragraph. Purpose of this paragraph is to present the clinical evidence in this field,
summarizing the mechanisms involved and the main epidemiological studies.
6.1. The Obesogenic Hypothesis
The term “obesogenic” related to EDCs was first developed in 2006 by Grün and Blumberg
([103]; see Section 4). Studies have shown how EDCs may alter energy homeostasis both in
cellular and animal models and in humans, although experimental data seem to be more consistent
compared to epidemiological data. EDCs actions involve several mechanisms: increase in number
and size of adipose cells, impairment of endocrine regulation of adipose tissue and adipocytokine
production, reduction of basal metabolic rate, changes in the regulation of appetite and satiety.
These effects are due to molecular actions of EDCs on cellular function via interaction with steroid
receptors and nuclear transcription factors, impairment of endocrine signalling transduction and
epigenetic mechanisms. In vivo and in vitro models mainly studied the following EDCs actions:
interaction with PPARγ and Retinoid X Receptor (RXR), anti-androgenic/xeno estrogenic action
and interaction with HPT axis. PPARγ is a nuclear transcription factor, which plays a crucial role in
adipocyte biology and is considered the principal regulator of adipogenesis [125,126]. PPARγ acts as a
heterodimer, associating with RXR, and regulating the expression of genes involved in adipogenesis
and adipocyte differentiation from stem cells [127]. In vivo and in vitro models have confirmed the
capacity of EDCs to induce adipogenesis and lipid storage in adipose tissue via interactions with
PPARγ [103,128–130]. EDCs interaction with PPAR -RXR may finally contribute to the development
of the pro-inflammatory status and imbalance in adipocytokine production typical of obesity and of
the metabolic syndrome [131,132]. EDCs exhibit anti-androgenic and xeno-estrogenic actions (well
described in other sections of this review); androgens and estrogens are involved in the regulation
of lipid and glucose metabolism and in the regulation of adipose tissue also [133,134]. Therefore,
EDCs may exert their obesogenic action inhibiting the androgen receptor pathway, enhancing the
estrogen pathway or reducing androgen conversion through the up-regulation of the aromatase
enzyme [135–137]. Thyroid hormones have a pivotal role in the regulation of basal metabolic rate and
energy expenditure [138]. The role of EDCs in the development of metabolic disease may therefore
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be related, at least in part, with the disruption of the HPT axis [139–141], discussed in a following
section (see Section 8). In addition to these well-known mechanisms, recently, other actions of EDCs
have been highlighted having a possible implication in the development of obesity. EDCs have been
shown to influence the function of metabolic physiological defences against oxidative stress [142],
thus enhancing the low-grade inflammatory milieu of obese subjects. Finally, in recent years, several
studies have suggested a contribution of gut microbiota which can be influenced by EDCs [143].
Both the gastrointestinal tract and its microbiota are likely to be exposed to EDCs through the diet.
EDCs dietary exposure have been shown to alter the composition of microbiota. These changes
are associated with abnormalities in the host gut immune homeostasis with subsequent changes in
cytokine production and hepatic lipid and glucose metabolism [144]. Table 1 summarizes the principal
obesogenic EDCs and their mechanisms of action.
Table 1. Principal obesogenic endocrine disrupting chemicals (EDCs) and the site of action.
Chemical Metabolite Site of Action
Phthalates DBP, BP, DHEP Steroid receptors (anti androgen), PPARs, RXR [128,137]
Phenolic compounds BPA Steroid receptors (xeno-estrogen), PPARs, RXR [131,140,141]
Pharmaceutical compounds DES Estrogen receptor [136]
Organotin compounds TBT PPARs, RXR [129,139]
Dioxins TCDD Aryl hydrocarbon receptor [144]
PCBs and POPs PCB 153-170-187 Aryl hydrocarbon receptor [130,144]
Pesticides DDT Steroid receptors [133,134]
Flame retardants Penta-DBE Steroid receptors [133,134]
Alkylphenols NP Steroid receptors [133,134]
Abbreviations: DBP: dibutyl phthalate; BP: Benzophenone; DHEP: diclofenac hydroxyethylpyrrolidine; PPAR:
Peroxisome proliferator-activated receptor; RXR: retinoid X receptor; BPA: Bisphenol A; DES: diethylstilbestrol;
TBT: Tributyltin; TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin; PCBs: Polychlorinated biphenyls; POPs: persistent
organic pollutants; DDT: dichlorodiphenyltri-chloroethane; penta-DBE: pentabrominated diphenyl ether;
NP: 4-nonylphenol.
6.2. Diabetogenic Hypothesis
Over the last decade, there has been a huge increase in the prevalence of T2D. This epidemiological
trend is consistent with the exponential increment in the production of synthetic chemicals, an evidence
that induced some authors to consider the possibility of a role of EDCs as diabetogenic compounds,
regardless of their influence on adipose tissue metabolism [145]. Diabetogenic compounds may exert
their action both impairing insulin production at the pancreatic beta cell level and disrupting insulin
sensitivity in peripheral tissues. EDC actions on pancreatic function can occur through different
mechanisms; for examples, TBT reduces beta cell mass and enhances beta cell apoptosis [146];
phthalates reduce beta cell insulin content [147]; BPA impairs insulin secretion [148]. With regard to
peripheral tissues, EDCs reduce insulin sensitivity acting on insulin targets, particularly in the liver.
In animal models, BPA alters hepatic glucose sensing, impairing glucokinase (GCK) specific activity [149].
6.3. Trans-Generational Effects of EDCs and Metabolic Disturbances
Effects of EDCs on adipogenesis and glucose metabolism may not limit to directly exposed
individuals. A huge amount of data emerged during recent years regarding trans-generational actions
of EDCs through the epigenetic modulation of regulatory networks. Indeed, animal models have
shown that BPA, TBT, pesticides and phthalate exposure determines an increase in the prevalence
of obesity and reproductive disease up to the third generation [150,151]. Skinner and his group
clearly demonstrated that this effect is secondary to epimutations in a network of genes known to be
associated with obesity and its complications [152]. Epigenetic modifications, including abnormal
DNA methylation have been also identified in genes involved in insulin sensitivity, such as the GCK
gene, after ancestral exposure to EDCs [153].
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6.4. Evidence in Humans
Although experimental animal models confirm a profound impact of chemical pollutants
on adipocyte physiology and glucose metabolism, evidence in humans is still scarce, with data
often conflicting. The reasons of the discrepancies are complex, probably the results of different
factors, including intrinsic features of each EDC, variability of EDCs distribution in the environment,
differential actions of EDCs, depending on the developmental time-window of exposure and
concomitant exposure to a mixture of chemicals, with a likely synergistic effect, known as cocktail
effect phenomenon [154]. This complexity renders difficult to build a strong epidemiological model
to study the mechanisms of action of EDC in humans and to understand the real clinical impact of
each EDC. Moreover, the main publications in the field regard cross sectional or case-control studies.
Longitudinal studies are still very limited; therefore, it is necessary to confirm or strengthen data
derived from experimental models and cross-sectional studies. Table 2 reports the main evidences
concerning the impact of EDCs on obesity and glucose metabolism impairment in humans.
Table 2. Impact of EDCs on measures of adiposity and metabolism.
EDC Population Endpoint
TCDD (Dioxin) U.S. Ranch Hand Veterans (Adults) Increased risk of T2DM [155]
TCDD (Dioxin) North Italy (Seveso incident, adults) Increased risk of T2DM (Female) [156]
Persistent Organic Pollutants Spain (Adults) Increased risk of metabolic syndrome [157]
Persistent Organic Pollutants Canada (Adults) Increased risk of metabolic syndrome [158]
BPA China (Adults) Increased BMI, waist circumference and decreasedinsulin sensitivity [159]
BPA NHANES (U.S., adults) Increased BMI and waist circumference [160]
Phthalates NHANES (U.S. Adults and children) Increased BMI [161]
Phthalates NHANES (U.S. Adults and children) Increased waist circumference, decreased insulinsensitivity (adult males) [162]
Phthalates Italy (Children) Increased waist circumference, decreased insulinsensitivity [163]
Abbreviations: TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin; T2DM: Diabetes mellitus type 2; BMI: Body Mass Index;
BPA: Bisphenol A; BMI: body mass index; NHANES: National Health and Nutrition Examination Survey.
7. Effects of EDCs on Prenatal and Postnatal Growth
Fetal growth restriction and premature birth have been associated with EDC exposure.
Exposure during critical periods of development, such as fetal and early postnatal life, may have
consequences. This is of importance for research, patient care, prevention and public health [164].
As EDCs are widely distributed in the environment, the majority of pregnant women in the United
States have detectable levels of multiple EDCs in their blood or urine [165,166]. Some epidemiological
studies have reported the correlation between prenatal exposure to EDCs and infant birth outcomes
but the results of these epidemiological studies are contradictory. Many investigators have explored the
relationship between EDC exposure and birth weight [167]. Lenters et al. examined 17 chemicals (six
phthalates, eight Perfluoroalkyl substances (PFAS), two PCBs and one oral contraceptive pill (OCP))
using Elastic Net Regression analyses highlighting previously unknown relationships between 4 of
these EDCs and birth weight: two phthalate metabolites (MEHHP, MOiNP), perfluorooctanoic acid
(PFOA), and p,p’-dichlorodiphenyl dichloroethylene (p,p’-DDE) were most consistently predictive of
term birth weight. In an adjusted, unpenalized regression model of the four exposures, a 2 SD increase
in natural log–transformed MEHHP, PFOA, and p,p’-DDE was associated with lower birth weight:
−87 g (95% CI:−137,−340 per 1.70 ng/mL),−43 g (95% CI:−108, 23 per 1.18 ng/mL), and−135 g (95%
CI: −192, −78 per 1.82 ng/g lipid), respectively; and MOiNP was associated with higher birth weight
(46 g; 95% CI: −5, 97 per 2.22 ng/mL) [167]. A meta-analysis conducted on European birth cohorts,
examining occupational EDC exposures using a job exposure matrix, found that pregnant women
exposed to more than one EDC class were more likely to have a low birth weight infant [168]. There is
Int. J. Mol. Sci. 2018, 19, 1647 14 of 44
also sufficient evidence that increased PFAS, especially Perfluorooctanoic acid (PFOA), exposure
is associated with low birth weight, whereas mixed results are reported for other EDCs and birth
weight [167,169]. For example, a meta-analysis, described an association between PCB 153 and low
birth weight [169] whereas Lenters et al. [167] did not find any association. Similarly, inconsistent
associations exist for phthalates and BPA [170–172], OCPs [167] and PBDEs [173,174]. In the following
paragraphs, we provide an overview on the exposure to the main EDCs, such as BPA, Persistent
organic pollutants (POPs) and PBDEs during intrauterine growth.
7.1. PBDEs
Flame retardants as PBDE are used in many consumer products such as polyurethane foams used
in furniture, mattresses, carpet pads, automobile seats, styrene plastics used for electrical appliances
and flame-retardant textiles [175]. The insulin-like growth factor (IGF) system is required for fetal
growth and a few studies have suggested that PBDE has the capacity to disrupt this system [176].
A 1 mg/kg prenatal exposure per day of BDE-99 has been described to induce an increase in IGF-I
gene expression in the uterus in rats [177]. In humans, only two studies have addressed these
relationships, one reporting in 149 women from Taiwan a positive association between BDE-196 in
breast milk and IGF-I levels in cord serum and negative relationships of IGF-I with BDE-99 and
other 86 compounds [178]. The second study reported a positive correlation between umbilical
cord serum PBDE levels and placental IGF binding protein 3 (IGFBP3) gene expression among
Chinese children living in one of the world’s largest electronic waste sites [179]. Nine epidemiological
studies assessed the relationship between PBDEs and birth weight; six of these reported a negative
association (four significant and two non-significant), two others reported no statistically significant
association, and one study suggested a negative association in male infants and a positive association
in females [174,180–182]. A further study described an association between increased PBDEs in
breast milk and adverse birth outcomes, including low birth weight, short birth length and chest
circumference [183]. Furthermore, a prospective Chinese birth cohort reported that maternal BDE-28
and BDE-100 were negatively associated with birth length, and birth weight, in males only [184].
On the contrary, the Canadian birth cohort GEStation Thyroid and Environment (GESTE) study did
not find an association between PBDE exposure and birth outcomes [173].
7.2. BPA
Many studies investigated the effects of BPA exposure on the fetus during pregnancy. Despite the
efforts, the relationship between BPA and fetal or neonatal growth indexes are inconsistent, and there is
not enough evidence to clarify if exposure to BPA during pregnancy affects only fetal growth at the time
of exposure, or if it affects postnatal growth also. BPA can readily cross the placenta, and some in vivo
experiments have demonstrated that it can cause adverse birth outcomes in offspring. For example,
oral administration of 10 mg/kg/day of BPA to pregnant rats caused a decreased number of neonates
and survival rate. In utero or neonatal exposure to BPA can alter offspring phenotype by stably altering
the epigenome, an effect that can be counteracted by maternal dietary supplements [185]. A study
measuring BPA levels in maternal blood and umbilical cord blood showed an increased risk for LBW,
and an adverse action of leptin and adiponectin in male neonates in the highest quartile of maternal
BPA exposure [186]. Furthermore, in 80 matching samples of pregnant women higher unconjugated
BPA exposure levels during first trimester and term were associated with sex specific reduction in birth
weight and increase in gestational length [187]. In the Mothers and Children’s Environmental Health
(MOCEH) study, a total of 788 mother-child pairs in the third trimester and 366 pairs in the neonatal
period who completed BPA assessment and fetal/children growth outcomes were included [188].
BPA measurements were conducted twice in the third trimester, using maternal urine, and once in
neonatal urine. The study suggested that BPA exposure was negatively associated with intrauterine
linear growth. In particular, 1 log-transformed unit of BPA/Creatinine increase of maternal urinary
BPA concentration in the third trimester was associated with a decreased femur length. In addition,
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1 log-transformed unit of BPA/Creatinine increase of prenatal BPA concentration resulted in increased
weight at birth.
7.3. POPs
PFASs and OCs are persistent, bio-cumulative chemicals that have been detected in maternal
blood during pregnancy and in cord blood at delivery. PFASs and OCs may act as EDCs, and in utero
exposure to these xenobiotics may have consequential developmental effects on the fetus. Animal
studies indicate that maternal PFAS exposure is associated with reduced fetal growth. However,
the results of human studies are inconsistent. A recent systematic review evaluated the data of
14 selected studies, 8 of which reported an in utero exposure [189]. Measures of birth weight showed a
continuous decrease after PFOA exposure although the importance of the association varied and many
results were not statistically significant.
Results relative to associations between Perfluorooctane Sulfonate (PFOS) exposure and birth
weight were also inconsistent. Higher PFOS and PFOA concentrations were reported overall to
be associated with an average decreased birth weight in most studies, however, few data were
significantly different. Another study measured perfluorohexane sulfonate (PFHxS), PFOS, PFOA,
and perfluorononanoate (PFNA) in 1202 mother-child pairs; overall, PFAS concentrations were not
associated with birth outcomes. Only PFOA, PFHxS, and PFNA showed weak, non-significant
associations with reduced birth weights ranging from 8.6 g to 10.3 g per doubling of exposure [190]. In
this context, considering the discrepancies between the studies, the impact of PFASs on public health
is unclear, but undoubtedly, the global exposure to PFASs warrants further investigation [191].
8. Effects of EDCs on the Thyroid Gland
Thyroid hormones (THs) are critical for normal growth and neurodevelopment, thus, it is
important that thyroid function must be maintained within normal physiological limits both during
prenatal and postnatal life. There is growing evidence that EDCs can disrupt thyroid homeostasis, even
though the most important knowledge on this topic derives from animal studies, while clinical studies
are still few and controversial [192]. The control of thyroid function involves a dynamic interaction
among the hypothalamic releasing hormone TRH, the pituitary Thyroid Stimulating Hormone (TSH),
and the TH that exist in two major forms: Thyroxine (T4) and T3. The thyroid gland synthesizes
THs principally in the form of T4, a pro-hormone. In target tissues, deiodinases 1 and 2 convert T4
into biologically active T3. The principal role of T3 is to regulate target gene transcription via its
nuclear receptor.
8.1. Iodine Deficiency
TH production is normally influenced by the contribution of some environmental micronutrients
such as selenium and iodine. In particular, the environmental availability of iodine and its active uptake
through the sodium/iodide symporter (NIS) potentially constitute the pathophysiological conditions
with which several EDCs can interfere. From this point of view, the most recent epidemiological data
(Indian Coalition for Control of Iodine Deficiency Disorders–ICCIDD, 2015) showed that there are still
areas of mild/moderate ID in European industrial countries also, although globally iodine deficiency
(ID) has improved since 1999. Furthermore, some tissues can regulate their own sensitivity to THs by
changes in the expression of various enzymes and transporters [192]. This leads to a situation in which
changes in TH action in specific tissues and cells does not reflect changes in circulating levels of THs.
Therefore, the evaluation of this parameter is not always reliable to highlight the clinical effects of EDCs,
and probably may explain some of the controversial results in the literature observed to date [192,193].
Finally, THs are required throughout fetal life and early childhood for proper brain development.
In humans, the fetal thyroid gland does not develop until the second trimester of pregnancy. Therefore,
the developing fetus is completely reliant on the maternal source of THs during the first half of
pregnancy [194]. In particular, the contribution of THs to the fetus is guaranteed by T4 readily crossing
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the placenta. In this context, even subtle changes in thyroid function of pregnant women are critical
for brain development during fetal life and can cause detrimental effects for the foetus. Therefore,
the feto-placental unit may become a target for the action of EDCs [194,195]. There is growing evidence
that the HPT axis may be targeted by EDCs, widespread in the environment. Thyroid disruption by
EDCs can occur at any level of the HPT axis including TH synthesis (perchlorate [196], thiocyanate [197],
phthalates [198], PCB [199], BPA [200], PBDEs [201]), release (phthalates [202], PCB [203], PBDEs [204]),
transport (phthalates [205], PCB [203], dioxins [206]), and metabolism (PCB [203], dioxins [206,207],
BPA [208]). TH action on target tissues can be disrupted too (PCB [209,210], PBDEs [211]) (Figure 1).
Most effects are due, in part, to structural similarities between some EDCs and THs. EDC effects,
however, must be evaluated taking into consideration the dependency of the thyroid gland on iodine
supply. Likely, the thyroid can adapt partially to adverse EDCs effects, as long as the iodine supply
is adequate. As ID still occurs in many countries of the world, this could facilitate and/or enhance
the anti-thyroid effects of EDCs. Certain risk groups show a greater tendency to suffer from the
consequences of even mild ID, including pregnant and breastfeeding women. Thus, in these groups ID
associated with exposure to EDCs may adversely affect the neuro-intellective development of future
generations [212].
8.2. Perchlorate and Thyocyanate
With regard to clinical studies on EDCs, those concerning perchlorate, thiocyanate and PCB
showed evidence of anti-thyroid effects and the possible relationship with iodine supply, prenatal
exposure and neuro-intellective development in the offspring [197,213–218]. For example, perchlorate
and thiocyanate decrease thyroidal iodine uptake by competitively inhibiting the NIS. Exposure to
perchlorate and thiocyanate, at least at low levels, occurs ubiquitously as they are naturally found in the
environment. In addition, perchlorate is also present in a wide range of products including fertilizers,
rockets, fireworks, airbag inflation systems, milk and even prenatal vitamins, whereas thiocyanate is a
metabolite of cyanide found in tobacco smoke and increased serum levels are observed in smokers [197].
In this regard, data from National Health and Nutrition Examination Survey (NHANES) 2001–2002
highlighted that in women with low urinary iodine (<100 µg/L) the association between urinary
perchlorate and decreased serum T4 was stronger in smokers than in non-smokers and in those with
high urinary thiocyanate levels. The authors suggested that the thiocyanate content in tobacco smoke
interacted with perchlorate diminishing iodine uptake and affecting thyroid function. In addition,
authors claimed that this effect could take place at commonly occurring perchlorate exposure [197].
In a cross-sectional study conducted in 200 first-trimester pregnant Thai women, environmental
exposure to perchlorate was found positively associated with TSH and negatively associated with free
T4. Thiocyanate is 15 times less potent than perchlorate as iodide competitor for NIS and it is probably
for this reason that thiocyanate exposure was positively associated with TSH only in a subgroup
of pregnant women with low iodine excretion [213]. Finally, a recent European study conducted as
part of a randomized controlled trial on antenatal thyroid screening, reported a relationship between
perchlorate exposure in first-trimester pregnant women with low urinary iodine (median 72 µg/L)
and measures of reduced cognitive function in the offspring at 3 years of age [214].
8.3. PCBs
PCBs and their hydroxylated metabolites are biologically active, accumulate in lipid tissues,
and are structurally very close to T4. PCBs may interfere with TH homeostasis in different ways:
by binding to transthyretin, by affecting the expression of TH-responsive genes and by antagonizing
the complexes from the TH-responsive elements [193]. Many studies in the literature show that both
prenatal and perinatal PCB exposure are associated with a variety of cognitive deficits in children.
It should be emphasized that the levels of exposure in some of the most recent studies are lower than in
the earlier one, yet they reported a negative impact on cognitive function [192,215–217]. The literature
regarding the relationship between PCB exposure and thyroid function evaluation in humans are
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controversial. PCBs are complex mixtures of various congeners, each with its own unique molecular
structure and potentially different toxic effect. Despite the advances in analytic methods to study these
mixtures in human tissue and environmental media, many difficulties remain in identifying reliable
markers of the effect of these EDCs on thyroid function [192,215].
Figure 1. Action of EDCs on the HPT Axis. The black arrows indicate the endocrine axis, the red
arrows indicate the organs/tissues targeted by the EDCs.
9. Effects of EDCs on Puberty
Environmental factors have been thought to account for the secular trend in pubertal timing
observed in several countries. Menarcheal age has been approximately 13 years for decades, whereas
200 years ago, it was 17 years [218]. Pubertal timing has been recognized as an endpoint possibly
influenced by exposure to EDCs and increasing exposure to these compounds has been suggested as
a possible factor accounting for the anticipating onset of human puberty [219,220]. The process by
which puberty occurs is primarily regulated by the activation of the hypothalamic-pituitary-gonadal
(HPG) axis and HPA axis through their chemical messengers, specifically the sexual hormones [221].
These axes are under the control of both inhibitory and stimulatory mechanisms [222]. Disruption
of this system by exposure to environmental hormone-mimicking substances may profoundly affect
pubertal development. The prevailing opinion on EDCs and puberty is that changes in pubertal timing
consist predominantly in an anticipation of female puberty [219,220]. However, both girls and boys
appear to experience changes in pubertal timing. A negative distortion of age distribution towards
younger ages for initial pubertal stages is observed in both sexes as well as a positive distortion of age
distribution towards older ages for the completion of puberty [218,223]. EDCs have many mechanisms
of action. Many EDCs are known to act as agonists of estrogen receptors or to antagonize androgen
receptor; progesterone receptors are also a potential target for many chlorinated EDCs [224]. Therefore,
EDCs may mimic naturally occurring estrogens and androgens in the body or they may potentially
cause overstimulation of hormonal pathways. In addition, EDCs might bind to a receptor within a cell
and block the functions of endogenous hormones, acting as antiestrogens and antiandrogens [225,226].
In humans, it is difficult to provide evidence of a causal relationship between changes in pubertal
timing and EDCs exposure [218]. Specifically, causation is difficult to demonstrate on the account of
exposure to low doses of tenths or even hundreds of chemicals starting in prenatal life. An additional
and critical concern is the potential lag between exposure, mainly in early life, which is particularly
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sensitive to EDCs effects, and observation of potential consequences on pubertal timing. Previous
Expert Panel and Endocrine Society Scientific statements reviewed the literature on human studies that
assessed associations between EDCs exposure and puberty timing [222,227]. The major studied EDCs
with regard to puberty include pesticides (dichlorodiphenyl trichloroethane (DDT) and its primary
metabolite DDE), polybrominated flame retardants (polybrominated biphenyls (PBB), PBDE), dioxin,
phthalate esters, and BPA.
9.1. Chlorinated Pesticides–DDT and DDE
With regard to pesticides, the main data came from the observation of early or precocious puberty
in children migrating to Belgium, for international adoption, formerly exposed to the estrogenic
insecticide DDT in the country of origin (Asia, Africa, and South America) via their biological
mothers, during pregnancy, and directly after birth. Median DDE concentrations were significantly
higher in adopted (n = 15/40) and non-adopted (n = 11/40) foreign-girls with precocious puberty
with respect to Belgian native girls with idiopathic or organic precocious puberty who showed
detectable concentrations in 2 out of 15 cases. Moreover, DDE levels were positively correlated with
age at immigration and negatively correlated with time since immigration [228,229]. The authors
hypothesized that emigration may interrupt exposure to DDT and precocious puberty could result
indirectly from withdrawal of the negative feedback of the sex steroids and their environmental
analogues and/or directly from accelerated hypothalamic maturation caused by sex steroids. Despite
the associations found in this study, the conclusions remain speculative; data on migrating children
showing early or precocious puberty depict the concept that environmental clues affect the timing of
puberty differently, depending on the life period when they come into action [218]. In the Michigan
angler cohort study, including 213 female offspring, in utero exposure to DDE was estimated using a
decay model based on maternal measurements. A significantly earlier menarche was observed among
girls with an increased in utero exposure. Specifically, menarche was 1 year earlier for every 15 µg/L
increase in in utero exposure to DDE [230]. Possible mechanisms for DDE effects include androgen
blocking, estrogen-mimicking effect or induction of aromatase. However, data are discordant, as none
of these studies associated puberty-timing measures, Tanner stages, and age at menarche with either
in utero or lactational DDE exposure [231]. A significant dose-response relation between serum DDT
concentrations and earlier menarche was also observed in 466 newly married, nulliparous female
Chinese textile workers [232].
9.2. PBDEs
PBDEs exposure during the peri-pubertal period was suspected to interfere with reproductive
development. The association between serum PBDEs and age at menarche was evaluated in 271
adolescent girls in the NHANES 2003–2004. Higher serum PBDEs concentrations were associated with
slightly earlier age at menarche: from the first to the fourth quartile of total PBDEs concentrations,
a higher percentage of adolescents in the higher PBDEs exposure group experienced menarche before
12 years [233]. In Italy, PBDE serum concentrations were determined in two different studies. A study
on 31 girls with idiopathic central precocious puberty showed a median PBDE level of 59 ng/g of
lipids [234], one order of magnitude higher than in those reported in a similar German study [235],
and less pronounced compared to samples from US girls. However, the upper quartile values were
comparable to the serum concentrations and was significantly associated with an increased risk of
earlier menarche [233]. In the second study, a case-control study including 37 girls with idiopathic
central precocious puberty and 56 with premature thelarche PBDE serum concentrations corrected
for total lipid content resulted significantly higher in girls with premature thelarche than in controls
and higher than in idiopathic central precocious puberty girls [236]. The effect of in utero exposure
to PBDEs on sexual maturation was evaluated in Michigan girls whose mothers were accidentally
exposed through diet to these compounds. In particular, pubertal development was assessed in 327
females exposed to PBBs in utero and, in many cases, throughout breastfeeding. Girls who were
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exposed in utero to high PBDEs concentrations and who were breastfed reported menarche 1 full year
earlier than unexposed girls (11.6 years vs. 12.2) or girls who were exposed only in utero (11.6 years
vs. 12.7 years). Perinatal exposure was associated with earlier pubic hair appearance in breastfed
girls, while no association was found with breast development [237]. These associations support the
hypothesis that pre- and postnatal exposure to organhalogens might affect pubertal events. Moreover,
considering that menarche and breast development are estrogen-dependent events whereas pubertal
hair growth is independent from estrogen levels, these findings suggest that PBBs may interact with
different pathways. Recently, associations between prenatal and childhood exposure to PBDE with
changes in pubertal timing were studied in a longitudinal cohort study including mainly families of
Mexican origin in Northern California. Prenatal concentrations of PBDE were associated with later
menarche in girls (RR earlier menarche = 0.5) and earlier pubic hair development in boys (RR earlier
pubarche = 2.0). No associations were seen between prenatal exposure and time of girls’ breast or
pubic hair development or of boys’ genital development and concentrations [238]. Although published
data are conflicting, findings suggested that PBDEs exhibit estrogenic and androgenic properties and
ubiquitous exposures may impact children’s pubertal development.
9.3. Dioxins
Dioxins are a group of well-characterized endocrine disrupters [239] and exposure to dioxins
was the only condition associated with delayed breast development as demonstrated in girls with
higher prenatal and lactational exposure in a small (n = 18) Dutch cohort study [240]. Slow breast
development to the adult stage was also demonstrated in Belgian children and was associated with
high dioxin exposure, whereas the age at menarche or pubic hair development showed no correlation
with exposure [241]. In 1976, as a result of a chemical explosion, residents of Seveso (Italy), experienced
the highest levels of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exposure. Pubertal development
was retrospectively examined among 282 women who were exposed post-natally or during childhood
and no change in age at menarche has proven to be associated with a 10-fold increase in TCDD serum
level [242].
9.4. Phthalates
The endocrine disrupting mechanism of phthalates is not fully understood; however, several
studies indicate a possible anti-androgenic effect as well as estrogen agonistic and antagonistic activities.
In general, phthalates have been associated with earlier puberty, although studies are not in agreement.
In Puerto Rico, a temporal trend toward premature thelarche in girls has been noted during the early
1980s [243]. Based on the data accumulated by the Premature Thelarche and Early Sexual Development
(PTESD) Registry, the estimated annual average incidence rate of premature thelarche in these Puerto
Rican girls was 8 cases per 1000 live female births from 1984 to 1993 [244]. Serum samples from
41 Puerto Rican girls with premature thelarche and 35 controls were analyzed to determine the
possible presence of pesticides and phthalate esters. Significantly higher phthalate levels were found
among the girls with premature thelarche; specifically, 68% of the girls with premature thelarche
had measurable levels of phthalates compared with 14% of control samples. These findings were
suggestive of a possible association between phthalate exposure and premature thelarche in girls [245].
The possible phthalate anti-androgenic effects were suggested by a cross-sectional study from 725
healthy Danish girls, where the highest quartile of phthalate excretion was found to be associated
with delayed pubic hair development [246]. However, in a subsequent longitudinal study, including
both boys and girls, pubic hair occurrence did not appear associated with phthalate, even in the
most exposed girls, whereas appeared anticipated in the most exposed boys, who also showed higher
levels of testosterone and lower levels of adrenal androgens [247]. Despite Frederiksen and co-authors
demonstrated no differences in urinary phthalate metabolite levels between girls with precocious
puberty and controls [246], more recently both plasma and urinary phthalate levels were found to be
significantly higher in girls with central precocious puberty compared to both peripheral precocious
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puberty and control groups [248,249]. Finally, in the Breast Cancer and the Environment Research
Program (BCERP) Puberty Study, age of menarche was demonstrated to be younger with increasing
levels of high-molecular weight phthalate, measured several years earlier [250].
9.5. BPA
The ubiquitous use of BPA provides great potential for exposure to its well-known estrogen-like
action. A recent review showed that only 7 out 19 analysed studies demonstrated a correlation between
BPA and puberty [251]. Conversely, most cross-sectional studies performed in girls with precocious
puberty demonstrated that serum or urinary BPA levels were significantly higher than in control girls,
suggesting a role for BPA in the etiology of idiopathic central precocious puberty [252,253]. Regarding
age at menarche, as endpoint in pubertal maturation, the association with urinary BPA was analysed
in the NHANES 2003–2010 study including data on 987 adolescent girls aged 12–19. Adolescent girls
with moderate BPA levels appeared to be less likely to have early onset of menarche than those with the
lowest levels (OR = 0.57; 95% CI = 0.30, 1.08) [254]. A recent study evaluating 655 girls aged 9–18 years
in Shanghai also suggested the association between BPA exposure and delayed age at menarche [255].
Girls with moderate to high BPA urinary levels were more likely to have delayed menarche compared
to girls with undetectable BPA. Moreover, among girls with detectable BPA levels, girls aged 9–12 years
were more likely to have reached pubic hair stage 2 (onset of puberty), while girls aged >15 years were
less likely to have reached pubic hair stage 5 (completion of puberty) [255]. In contrast with previously
described studies, a multi-ethnic group of 192 healthy 9-year-old girls did not report any significant
associations with breast and pubic hair status in relation to BPA exposure [256]. Similar to the other
EDCs, the conflicting results among published studies do not allow the establishment of a clear role of
BPA in timing pubertal changes.
10. Effects of EDCs on Fertility
In the last 40 years several studies showed a decline in semen quality [257,258], evaluated as
significant decrease in total sperm count, motility, viability and normal shape, resulting in a reduction
in the chances to procreate [259]. The causes of this decline are still under investigation but it has
been suggested that the exposure to environmental chemicals such as EDCs, during intrauterine
development and in adulthood, could be a potential cause of male reproductive disorders [260].
Indeed, recent studies reported an increase in hypospadias and cryptorchidism in association with
maternal exposure to environmental pollutants [192,261]. In addition, female fertility seems to be
affected by exposure to EDCs [261] as reported in epidemiological studies in humans, in animal
models and in many in vitro studies [262,263]. EDCs interfere with the steroid hormone levels and
alter function and structure of reproductive organs [192]. Epigenetic mechanisms also play a pivotal
role in male and female infertility. Indeed, EDC-induced reproductive disorders have been associated
with DNA epigenetic modification (mostly DNA methylation) and have been proven in animal models
across multiple generations [192,264]. As mentioned above EDCs effects on human fertility are still
unclear as shown by the discordant results of the various studies. The timing and dose of EDCs
can result in different phenotypes, therefore, investigating the critical exposure window appears to
be essential to understand their different effects. Moreover, the human population is exposed to a
mixture of EDCs (previously define as cocktail effect), making it difficult to study the effect of a single
EDC on fertility and increasing the variability of results. The majority of studies has investigated the
effect of pesticides, industrial chemicals and related substances (phthalates, BPA, PCB), dioxin and
dibenzofurans on EDCs-induced infertility [192].
The main studies reporting on the effects of EDCs on fertility in women and men are reported in
Tables 3 and 4 respectively.
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Table 3. Recent evidences on the effects of EDCs on fertility in women.
Contaminant Substrate Cohort Results
BPA Urine
25 Turkish prepubertal
girls with premature
thelarche (PT), 25 healthy
prepubertal girls
The median urinary concentrations of BPA were found to be
significantly higher in the PT group compared to the healthy
control group, weak positive correlation between uterus
volume, estradiol and luteinizing hormone [265]
BPA, phthalates
Urine from
mothers during
first, second, and
third trimesters
of pregnancy.
120 female prepubertal
subjects
Phthalate metabolites were associated with higher serum
testosterone concentrations in prepuberty while a number of
metabolites measured in the third trimester were associated
with higher DHEA-S. MEHP levels across pregnancy were
associated with lower odds of having a Tanner Stage >1 for
breast development, while MEHP in the third trimester was
associated with higher odds of having a Tanner Stage for
pubic hair development >1 [266]
BPA Urine 268 infertile womendiagnosed with PCOS
BPA was detected in all women. Increased BPA correlated
with decreased antral follicle count and was negatively
associated with AMH and day-3 FSH levels, but neither of
these reached statistical significance [267]
BPA Urine 256 women No associations between urinary BPA concentrations and IVFoutcome [268]
BPA Urine
143 patients with
endometriosis, 287
healthy women
No associations between BPA concentrations and
endometriosis. Positive association with non-ovarian pelvic
endometriosis [269]
Phthalate
metabolites, BPA Urine 221 women
BPA and MCOP (or its precursors) were associated with
shorter luteal phase. DEHP metabolites were associated with
reduced early pregnancy loss [270]
Phthalate
metabolites Urine 229 women
No significant association with MBP, MBzP and MEHP.
Urinary concentration of MEP was associated with a
decreased fecundity [271]
Phthalate
metabolites Urine 128 women
Pregnancy loss was increased in women with urinary increase
in MEHP [272]
Pesticides Follicular fluid 94 women of infertilecouples
Higher concentrations of any studied PCBs and pesticides are
associated with thinner endometrial thickness and affected
embryological ICSI outcomes [273]
Dioxins, PCBs,
PBDEs, PBBs,
HBCDs, OC
pesticides
Adipose tissue
and serum
samples
55 patients and 44
healthy women
Significant associations between deep infiltrating
endometriosis and adipose tissue levels of PCB, PBDE, PBB,
benzenes and organochlorine pesticides [274]
Abbreviations: BPA: Bisphenol A; DHEA-S: dehydroepiandrosterone sulphate; MEHP: monoethylhexyl phthalate;
PCOS: Polycystic Ovarian Syndrome; AMH: Anti-Müllerian hormone; FSH: Follicle-Stimulating Hormone; IVF:
in vitro fertilization; MEP: mono-ethyl phthalate; MBP: monobutyl phthalate; MBzP: monobenzyl phthalate;
MCOP: monocarboxyoctyl phthalate; DEHP: di-(2-ethylhexyl) phthalate; ICSI: Intracytoplasmic Sperm Injection;
ART: assisted reproductive technologies; OCP: Oral contraceptive pill; PCBs: Polychlorinated biphenyls;
PBDEs: Polybrominated diphenyl ethers; PBBs: polybrominated biphenyls; HBCDs: hexabromocyclododecanes;
OC: organochlorine; POPs: Persistent organic pollutants; BFRs: Brominated flame retardants; PCDDs:
polychlorinated dibenzodioxins.
Table 4. Recent evidences on the effects of EDCs on fertility in men.
Contaminant Substrate Cohort Results
BPA Semen and serum
365 semen samples.
Maternal serum collected at
18 and 34 weeks’ gestation
Sperm concentration and motility were
significantly correlated with maternal serum
BPA levels [275]
BPA Semen and urine 215 healthy young men(18–23 years)
BPA levels were significantly and negatively
correlated with sperm concentration. No
significant associations were found among BPA
and other semen quality parameters or
reproductive hormone levels [276]
BPA Cord blood 283 neonates
Positive association of BPA levels with
testosterone, estradiol, and progesterone levels
in boys [277]
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Table 4. Cont.
Contaminant Substrate Cohort Results
BPA, phthalates
Urine from 1st,
2nd, 3rd
trimesters of
pregnancy
109 boys
Exposure to phthalates during the 3rd trimester
associated with lower odds of having Pubic
Hair Tanner stage >1 for and higher
peripubertal SHBG levels [266]
BPA, PCBs Plasma andsemen 191 men
Seminal BPA, but not plasma BPA, was
negatively associated with sperm concentration
and morphology. PCB was negatively
associated with testosterone, free testosterone,
free androgen index and DHT in plasma [278]
BPA Placenta 28 cases and 51 healthycontrols in newborns
Increase of BPA levels are associated with of
cryptorchidism and hypospadias [279]
Phthalate Urine, semen andblood 796 healthy man
Association with low semen quality and
alteration of reproductive hormones even with
a dose below the reference doses [280]
Phthalate Serum 112 adolescents
Highest exposure of one DiNP metabolites
associated with lower total testicular volume,
higher levels of FSH and lower semen volume.
Men in the highest exposure of one DEHP
metabolite show lower semen volume [281]
Phthalate
metabolites Urine and semen 501 healthy man
Association between urinary metabolites and
lower total sperm counts and concentrations,
larger sperm head sizes, higher proportions of
megalo head sperm morphology. MEHP was
significantly associated with higher sperm
motility [282]
Pesticides Blood 189 healthy young men
The total intake of fruit and vegetables was
unrelated to semen quality. Intake with
low-to-moderate pesticide residues was
associated with a higher total sperm count and
sperm concentration [283]
Organochlorine
Pesticides
Environmental
level
963 cryptorchid men;
678 hypospadias;
65 micropenis;
587,142 controls
Prevalence rates for cryptorchidism,
hypospadias and micropenis were significantly
greater in areas of high environmental
exposure to pesticides in relation to those with
low exposure [284]
Pesticides
(atrazine) Drinking water
343 cases with hypospadias
and 1422 male controls
No association between hypospadias and daily
maternal atrazine exposure during the critical
window of genitourinary development [285]
Pesticides Semen
2122 men who underwent
andrological investigation
for couple infertility
Exposure to pesticides was associated with a
significantly higher risk of asthenozoospermia
and necrozoospermia [286]
Pesticides Serum and semen 99 rural and 36 urban men(18–23 years)
Rural men had poorer sperm morphology,
higher sperm count, and lower LH levels than
urban subjects. Maternal farming during
pregnancy was associated with larger
anogenital distance and testis volume [287]
PCBs,
PCDD/Fs,
and PBDEs
Subcutaneous
adipose tissue
biopsies
44 cryptorchid cases,
and 38 controls
Prenatal exposure to PCDD/Fs and
PCDD/F-like PCBs may be associated with
increased risk for cryptorchidism [288]
Abbreviations: BPA: Bisphenol A; yr: years, SHBG: Sex Hormone Binding Globulin; PCBs: Polychlorinated
biphenyls; DHT: Dihydrotestosterone; DEHP: di-(2-ethylhexyl) phthalate; DBP: Dibutyl phthalate, DEP: Diethyl
phthalate; DOP: Di-n-octyl phthalate; MBzP: monobenzyl phthalate; MEHP: monoethylhexyl phthalate; DiNP:
diisononyl phthalate; FSH: Follicle-Stimulating Hormone; 2,4-D: 2,4-Dichlorophenoxyacetic acid; LH: luteinizing
hormone; PCDD/Fs: polychlorinated dibenzo-p-dioxins and furans; PBDEs: Polybrominated diphenyl ethers.
11. EDCs and Carcinogenesis
The depiction of cancer as a genetic accident, explained by the so-called somatic mutation
theory (SMT), which has dominated this field for some decades, is increasingly questioned for
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both epidemiological and molecular reasons [289]. Therefore, the terminology still in use–initiation/
promotion, and the clear separation among genotoxic and non-genotoxic agents-strictly connected to
this specific context needs a critical review. EDCs in adults, have quite different effects compared to
childhood and fetal life, and act mostly as morphogens, altering cell differentiation and interfering
with the epigenetic programming of cells, tissues and organs, opening the way to chronic inflammatory,
metabolic and cancerous diseases. The SMT model becomes questionable. The real limitation of the
SMT model is to be a linear, reductionist, mechanistic model. Indeed, in this model, carcinogens are all
agents hypothetically endowed with sufficient “power” to directly damage DNA or to disrupt some
key cellular metabolic processes in a potentially irreversible way [290], while the substances lacking
this “power” may act as cocarcinogens, essentially by promoting the action of carcinogens. On the
other hand, in the context of the emerging systemic and dynamic genomic models, all carcinogenic
factors act initially through epigenetic mechanisms: hypomethylation of the whole DNA sequence,
hypermethylation of the regulatory/tumour suppressor genes, activation of the mobile sequences and
the microRNA networks acting as real “sensors” of stress/danger [291]. It is important to emphasize
that in this context, mutations should not be considered the cause of cancer, but the consequence of
progressive genomic instability induced by a prolonged exposure to many different stressors. In a
dynamic model like this one, also the (co)cancerogenic role of many EDCs would be better explained.
In particular, an early exposure to these ubiquitous substances, mainly during the prenatal period,
could induce the abovementioned reactive, potentially defensive epigenetic changes, while a subsequent
interaction with the same (or similar) stressors would determine the neoplastic transformation of this
poorly programmed tissue. In fact, within such a model, the Knudson’s “Two-Hit” Hypothesis of cancer
causation (hitherto recognized only in some rare forms of cancer) [292] would become a sort of universal
pathogenic theory, better explaining why currently all non-communicable diseases are increasing all
over the world, and we are observing a continuous anticipation in the age of onset of the damage. This is
obviously the context of the DOHaD theory which is essentially based on three closely interconnected
concepts: fetal programming, developmental plasticity, epigenetic mismatch [293]. In such a context,
cancer (above all, child and juvenile cancer) should be considered as a dysontogenic process [294],
like all other chronic diseases-inflammatory, metabolic and degenerative-that are increasing in the world.
Renzo Tomatis, the former Director of the International Agency for Research on Cancer (IARC)
and founder of the IARC Monographs program [295], had already proposed this hypothesis over
40 years ago [296], specifically in relation to what is generally considered the world’s first drug
disaster, prenatal exposure to diethylstilbestrol (DES). In a recent update after a 40-year follow up,
the association between prenatal DES exposure and clear cell adenocarcinoma of the vagina and
cervix has been confirmed [297]. At that time, the link between the exposure of pregnant animals to
chemical carcinogens and the occurrence of tumours in the progeny was well documented. Scientists
had already hypothesized that the increased risk of cancer in DES girls would be due to exposure to
stilbestrol during pregnancy [298]. Tomatis showed that the exposure to DES of pregnant rats resulted
in an increased incidence of tumours at specific sites in untreated animals of the second and third
generations [299]. In those years, epigenetics was only a theory and it was not possible to hypothesize
an epigenetic molecular mechanism at the origin of these unexpected cases of transgenerational
carcinogenesis. Only after decades scientists could demonstrate that DES is a powerful endocrine
disruptor that interferes with the expression of several uterine genes involved in tissue patterning,
such as Wnt Family Member 7A (Wnt7a) [300], Homeobox A9 (Hoxa9), Homeobox A10 (Hoxa10),
and Homeobox A11 (Hoxa11) [301], contributing to changes in tissue architecture and morphology.
With regard to this, recently performed in vitro and in vivo experiments showed that Homeobox
C6 (HOXC6) is an estrogen-regulated gene in breast cancer cells which expression may be induced
by exposure to estrogenic EDCs such as BPA, in competition with estradiol (E2) [302]. Exposure
to E2 or BPA altered the epigenetic status of the HOXC6 promoter, including increased histone
H3K4-trimethylation and histone acetylation, ultimately resulting in HOXC6 gene activation [302].
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The DES tragedy not only showed the carcinogenic mechanisms of an endocrine disruptor, but
also elucidated how the carcinogenic process can begin in the foetus as altered epigenetic tissue
programming (first hit/tumour initiation). In the following years, other studies showed how an
early-life exposure to DES during development of the uterus may enhance the penetrance of a
tumor-suppressor gene defect in the adult and revealed that a second exposure could trigger the
following phases of the neoplastic process (second hit/tumour promotion) [303]. With the intention to
deepen the mechanism of DES-induced carcinogenesis, a recent study evaluated miRNA expression
in the Syrian golden hamster model, receiving DES on the day of birth [304]. In particular, this study
highlighted how DES-induced neoplasia in the hamster uterus includes a spectrum of miRNA expression
alterations, providing key new insights on the epigenetics contribution to EDCs carcinogenesis.
The fact that the in utero exposure to EDCs predisposes both to neoplastic forms and to
genito-urinary malformations demonstrates that the implicated molecular mechanisms are, at least
in this early period of life, essentially of epigenetic nature, perturbing cell differentiation and tissue
development (fetal programming). An important confirmation of the link between the morphogenetic
and the carcinogenic potential of EDCs comes from the numerous studies on TCDD (the so-called
Seveso dioxin) [305] already recognized by the IARC as a potent carcinogen [306], and PCBs [307].
These studies showed how TCDD and PCBs act in the fetus by altering the development of the
mammary gland, an organ physiologically characterized by a very high degree of plasticity, having to
assume various conformations and to perform different activities in different periods of life, particularly
during and after pregnancy [308].
It is not surprising that tumours most directly and frequently related to EDCs affect tissues and
organs belonging to the endocrine system, in particular the mammary gland [309] and the prostate [310].
Like DES, BPA is an estrogen-like EDC that induces persistent epigenetic changes in the fetus,
mainly in the developing uterus and breast. The molecular mechanisms by which epigenetic alterations
would produce an increased risk of breast neoplasia after in utero exposure to both molecules have
been recently illustrated [311]. A model summarizing the main pathways potentially involved in the
BPA action in prostate cancer was recently proposed by Di Donato and co-workers, showing androgen
and estrogen receptor mediated gene transcription, contributing to either enhancement or inhibition of
cell proliferation. This could occur through epigenetic modifications such as those associated with
abnormal activity of histone-modifying enzymes (sirtuins, LSD/KDM lysine-demethylases), recruited
to chromatin by steroidal receptors [312]. Another study performed in zebrafish proposed that also the
BPA effects on female reproductive function could involve epigenetic mechanism [313]. The inhibitory
action of BPA on the ovary could be due to its capacity to down-regulate the expression of the
luteinizing hormone/choriogonadotropin receptor (lhcgr) both decreasing and increasing histone
methylation and interfering with DNA methyl transferases [313].
Returning to dioxin, it was reported that the pro-lymphomatous chromosomal translocation
(t14; 18) increased significantly in normal subjects [314]. Even more interestingly, the same translocation,
leading to the continued expression of the anti-apoptotic gene B-cell lymphoma 2 (BCL-2), and thus
to the formation of immortalized lymphocyte clones, was described in subjects chronically exposed
to pesticides [315]. This clearly shows how totally different molecules, capable of acting as EDCs,
can induce the formation of specific chromosomal arrangements, i.e., of reactive and potentially
defensive changes in affected cells. The specific modalities of action of EDCs allow and to some extent
force us, to consider cancer not a genetic incident, due to stochastic DNA mutations, but the product of
a disturbed early epigenetic programming of tissues and organs and of further molecular mechanisms
potentially adaptive and defensive towards an environment in continuous and dramatic transformation.
12. Conclusions
Most of the knowledge on the harmful effects of EDCs comes from animal studies. Observation
of wildlife remains crucial for human health and understanding of the environment, including the
effect of chemicals, in particular of those having endocrine and metabolic effects. In recent years,
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a lot of data has arisen relative to the effects of EDC exposure on metabolism, obesity and its
complications, neurodevelopment and behaviour, intrauterine growth, thyroid function, puberty,
fertility, and carcinogenesis.
Studies to date underline the brain as a vulnerable target of EDCs. Many of the reviewed studies
present significant limitations, including lack of replication, limited sample sizes, retrospective design,
publication biases, inadequate matching of cases and controls, and the use of non-standardized tools
to diagnose conditions as ASD, although the overall evidence on a pathogenetic role for EDCs is
compelling. Experimental animal data show numerous neurobiological changes caused by EDCs,
including neuronal development, properties of synaptic organization, neurotransmitter synthesis and
release, and structural organizational effects on the developing brain. In addition to this, there is
growing evidence on associations between EDC exposure and fetal and postnatal growth, however,
we should also underline that findings are often conflicting, and methodological limits are present.
For example, with regard to EDCs disrupting thyroid homeostasis, widely diffused in the environment,
often it is not possible to find a correlation with circulating TH levels both for methodological issues
and for pathogenetic reasons. Some peculiar features of the HPT axis promote the interaction between
the environmental supply of iodine and the EDCs antithyroid effects, besides on the neuro-intellective
development. This interaction could be particularly significant in high-risk situations and in the most
vulnerable groups as in pregnant women, prenatal and perinatal periods.
Multiple lines of evidence suggest a role of EDCs exposures in the modulation of human pubertal
timing. However, published data on human pre- or neonatally and postnatally exposed are scarce and
no firm conclusions can be drawn. In this context, further studies are needed to address the question of
which EDCs mainly affect puberty and how we can reduce relevant exposures. With regard to fertility,
studies once again show conflicting results. A possible cause could be the “cocktail effect” and the
differences in environment, therefore, further studies are absolutely needed to clarify the role of EDCs
on male and female reproductive health.
With regard to carcinogenesis, the most powerful pro-carcinogenic mechanisms of endocrine
disruptors, seem to be related to their ability to epigenetically interfere with the embryo-fetal
programming of tissues and organs (Figure 2). Essentially the proposed embryo-fetal programming
occurs by altering the regulation of genes involved in cell cycle, cell proliferation, apoptosis and other
key signalling pathways. In view of this consideration, a radical change in the dominant model of
carcinogenesis and, to a large extent, in the current pathogenetic models inherent to chronic diseases
that are continuously increasing in the world, is likely necessary.
Figure 2. Importance of EDCs driven epigenetic effects during life course and potential consequences
across generations according to the Developmental Origins of Health and Disease (DOHaD) theory.
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